CTSO

Cytosorbents Corp (CTSO) - 10-K Summary for Fiscal Year Ended December 31, 2025

Business Context and Reporting Period

Cytosorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. The reporting period covers the fiscal year ended December 31, 2025. The Company's lead product, CytoSorb, is approved in the European Union (EU) and distributed in over 70 countries. The Company is actively pursuing FDA approval in the United States for DrugSorb-ATR, an investigational device designed to remove blood thinners during cardiac surgery.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 4.1% year-over-year, driven by strength in distributor and strategic partner sales outside Germany, partially offset by lower direct sales in Germany.
• Profitability Improvement: The operating loss decreased by 10.4% to $14.7 million, primarily due to revenue growth and improved gross margins.
• Foreign Currency Impact: The Company recorded a $9.3 million gain on foreign currency transactions in 2025, compared to a $4.2 million loss in 2024, due to the strengthening of the Euro against the U.S. dollar.
• Restructuring: In Q4 2025, the Company initiated a workforce and cost reduction plan, incurring $0.5 million in restructuring charges (10% workforce reduction).
• R&D Expenses: Research and development expenses decreased 33.2% to $5.1 million, largely due to the completion of the pivotal STAR-T clinical trial.

Guidance, Outlook, and Risks

• Regulatory Status (DrugSorb-ATR): The FDA denied the Company's initial De Novo application in April 2025. Following an appeal in July 2025, the FDA upheld the denial but confirmed no safety issues, requesting additional information for the desired label. The Company decided not to pursue a final appeal and is preparing a new De Novo submission with additional real-world data. A regulatory decision is expected within 150 days of resubmission.
• Health Canada: The Company withdrew its request for reconsideration of a June 2025 refusal, opting to wait for better visibility from the FDA before resubmitting.
• Liquidity and Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With approximately $7.8 million in total cash and a cash burn of $12.8 million in 2025, current resources may not be sufficient to fund operations beyond the next 12 months without additional financing.
• Capital Resources: The Company amended its credit facility with Avenue Capital Group in November 2025, drawing an additional $2.5 million and extending the interest-only period. A further $2.5 million tranche is available contingent on FDA approval of DrugSorb-ATR by December 31, 2026.
• Stock Listing: The Company is not in compliance with Nasdaq's minimum bid price requirement (stock closed at $0.64 on Dec 31, 2025). It has filed for a 180-day extension to regain compliance, potentially via a reverse stock split.
• Internal Controls: The Company identified material weaknesses in internal controls over financial reporting related to stock-based compensation accounting and financial statement consolidation processes.

Key Facts for Investor Verification

• Regulatory Timeline: Verify the expected timing of the new De Novo submission to the FDA and the subsequent 150-day review period for DrugSorb-ATR.
• Cash Runway: Confirm the Company's ability to reach the projected operating cash flow break-even in the second half of 2026 given the current cash balance and burn rate.
• Debt Covenants: Review the specific operating cash burn targets required under the amended Avenue Capital Group loan agreement to avoid default.
• Nasdaq Compliance: Monitor the Company's progress in regaining compliance with Nasdaq listing standards by the March 31, 2026 deadline.
• Internal Control Remediation: Assess the progress of remediation efforts for the identified material weaknesses in financial reporting controls.